Product: Telehealth access to compounded GLP-1/GIP containing tirzepatide, plus a separate lower-dose microdosing pathway. Branded Ozempic is offered alongside, with a Wegovy pill listed as coming soon.
Process: A short online quiz, review by a licensed clinician, then medication shipped to the door. Gala operates as the platform; prescribing and dispensing sit with independent third parties.
Support: Ongoing clinician oversight plus a companion tracking app on iOS and Android for logging injections, weight and side effects.
Effectiveness: Tirzepatide activates both GLP-1 and GIP receptors. In SURMOUNT-1, the highest dose produced a mean 20.9% body weight reduction across 72 weeks. Compounded tirzepatide is a distinct product from Zepbound or Mounjaro.
Cost: $179/month on the annual plan and $199/month on the three-month plan. Microdosing runs $149/month annually. All doses are covered at the stated rate with no tiered pricing.
User Experience: Roughly 4.5 stars across more than a thousand Trustpilot reviews, with praise concentrated on affordability and a simple sign-up. The recurring criticism concerns dosing and delivery consistency.
Safety: Available in all 50 states, LegitScript certified and HIPAA compliant. Clinicians screen medical history before any prescription is issued.
Pros:
- Cheapest microdose tier: $149/month is the lowest microdose price of any platform reviewed here.
- Flat dose pricing: Titrating upward never raises your monthly cost.
- Dual-platform app: Tracking on both iOS and Android, which no other compounded-only program here matches.
- Nationwide reach: All 50 states with no insurance requirement.
Cons:
- Annual lock-in: The $179 headline needs a twelve-month commitment; shorter plans cost more.

